<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/28986/phase-3-agent-study-primary-endpoint-is-response-rate-tumor-shrinkage-pfs?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Phase 3 AGENT Study: Primary Endpoint Is Response Rate, T...

Name: Phase 3 AGENT Study: Primary Endpoint Is Response Rate, T...
Uploaded: 2019-06-04T07:15:27
Duration: 1 min 45 s
Description: Anders Rabbe CEO Of Isofol Medical Discusses Phase 3 AGENT Study: Primary Endpoint Is Response Rate, Tumor Shrinkage, & PFS .

Phase 3 AGENT Study: Primary Endpoint Is Response Rate, Tumor Shrinkage, & PFS

00:01:45

Annual Meeting

3 years 308 Views

Share Add to Report 0 0

Embed (Iframe):

<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/28986/phase-3-agent-study-primary-endpoint-is-response-rate-tumor-shrinkage-pfs?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Embed (Object):

<div class="embed-responsive embed-responsive-16by9"><object width="640" height="360"><param name="movie" value="https://oncologytube.com/videoEmbed/28986/phase-3-agent-study-primary-endpoint-is-response-rate-tumor-shrinkage-pfs?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit="></param><param name="allowFullScreen" value="true"></param><param name="allowscriptaccess" value="always"></param><embed src="https://oncologytube.com/videoEmbed/28986/phase-3-agent-study-primary-endpoint-is-response-rate-tumor-shrinkage-pfs?channelName=AnnualCancerMeeting&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" allowscriptaccess="always" allowfullscreen="true" width="640" height="360"></embed></object></div>

Link (HTML):

<a href="https://oncologytube.com/v/28986?channelName=AnnualCancerMeeting"><img src="https://oncologytubecom.cdn.ypt.me/videos/video_190604191527_2aaf/video_190604191527_2aaf.jpg?cache=15669162531678829655">Phase 3 AGENT Study: Primary Endpoint Is Response Rate, Tumor Shrinkage, & PFS</a>

Link (BBCode):

[url=https://oncologytube.com/v/28986?channelName=AnnualCancerMeeting][img]https://oncologytubecom.cdn.ypt.me/videos/video_190604191527_2aaf/video_190604191527_2aaf.jpg?cache=15669162531678829655[/img]Phase 3 AGENT Study: Primary Endpoint Is Response Rate, Tumor Shrinkage, & PFS[/url]

Sign in now!

Permanent Link

URL Friendly (SEO)

Current Time (SEO)

Category:

Colorectal

Description:

Anders Rabbe CEO Of Isofol Medical Discusses Phase 3 AGENT Study: Primary Endpoint Is Response Rate, Tumor Shrinkage, & PFS .